Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2019-01-31285,2019,Shaker 2019 J Allergy Clin Immunol Pract,870000,chronic spontaneous urticaria (csu) screening test VERSUS None IN Healthy; Age- 19 to 40 years; Gender- Both; Country- United States.,31751758,Healthy; Age- 19 to 40 years; Gender- Both; Country- United States.,chronic spontaneous urticaria (csu) screening test,Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.,None,NE
2019-01-31152,2019,Zhang 2019 PLoS One,220000,"universal non-invasive prenatal testing VERSUS Contingent non-invasive prenatal testing IN Specific disease- down syndrome; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Canada; Other- Pregnancy.",31800591,"Specific disease- down syndrome; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Canada; Other- Pregnancy.",universal non-invasive prenatal testing,Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.,Contingent non-invasive prenatal testing,NE
2019-01-31152,2019,Zhang 2019 PLoS One,Cost-Saving,"contingent non-invasive prenatal testing VERSUS Serum-only testing IN Specific disease- down syndrome; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Canada; Other- Pregnancy.",31800591,"Specific disease- down syndrome; Age- 19 to 40 years, 41 to 64 years; Gender- Female; Country- Canada; Other- Pregnancy.",contingent non-invasive prenatal testing,Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.,Serum-only testing,SE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,10000,Edoxaban VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Edoxaban,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,12000,Dabigatran VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Dabigatran,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,17000,Dabigatran VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Dabigatran,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,18000,Rivaroxaban VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation ; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation ; Age- Adult; Gender- Both; Country- Thailand.,Rivaroxaban,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,21000,Edoxaban VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Edoxaban,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30803,2019,Rattanachotphanit 2019 Pharmacoeconomics,22000,Apixaban VERSUS Warfarin adjusted dose IN Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,30387074,Specific disease- Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Apixaban,Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding.,Warfarin adjusted dose,NE
2019-01-30343,2019,Smith 2019 AJR Am J Roentgenol,800000,nephron-sparing surgery VERSUS Standard/Usual Care- Active Surveillance IN Specific disease- bosniak iif renal cyst; Age- 41 to 64 years; Gender- Female; Country- United States.,30779659,Specific disease- bosniak iif renal cyst; Age- 41 to 64 years; Gender- Female; Country- United States.,nephron-sparing surgery,Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis.,Standard/Usual Care- Active Surveillance,NE
2019-01-30343,2019,Smith 2019 AJR Am J Roentgenol,Dominated,nephron sparing surgery VERSUS active surveillance IN Specific disease- bosniak iif renal cyst; Age- 41 to 64 years; Gender- Male; Country- United States.,30779659,Specific disease- bosniak iif renal cyst; Age- 41 to 64 years; Gender- Male; Country- United States.,nephron sparing surgery,Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis.,active surveillance,NW
2019-01-30343,2019,Smith 2019 AJR Am J Roentgenol,Dominated,nephron-sparing surgery VERSUS Standard/Usual Care- Active Surveillance IN Specific disease- bosniak iii renal cyst; Age- 41 to 64 years; Gender- Female; Country- United States.,30779659,Specific disease- bosniak iii renal cyst; Age- 41 to 64 years; Gender- Female; Country- United States.,nephron-sparing surgery,Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis.,Standard/Usual Care- Active Surveillance,NW
2019-01-30343,2019,Smith 2019 AJR Am J Roentgenol,Dominated,nephron-sparing surgery VERSUS Standard/Usual Care- Active Surveillance IN Specific disease- bosniak iii renal cyst; Age- 41 to 64 years; Gender- Male; Country- United States.,30779659,Specific disease- bosniak iii renal cyst; Age- 41 to 64 years; Gender- Male; Country- United States.,nephron-sparing surgery,Active Surveillance Versus Nephron-Sparing Surgery for a Bosniak IIF or III Renal Cyst: A Cost-Effectiveness Analysis.,Standard/Usual Care- Active Surveillance,NW
2019-01-30092,2019,Windegger 2019 Vox Sang,Cost-Saving,home-based subcutaneous immunoglobulin VERSUS Standard/Usual Care- Hospital-based intravenous immunoglobulin IN Specific disease- secondary immunodeficiency; Age- Adult; Gender- Both; Country- Australia; Other- SID specifically acquired hypogammaglobulinaemia secondary to malignancy or associated treatment.,30883804,Specific disease- secondary immunodeficiency; Age- Adult; Gender- Both; Country- Australia; Other- SID specifically acquired hypogammaglobulinaemia secondary to malignancy or associated treatment.,home-based subcutaneous immunoglobulin,Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.,Standard/Usual Care- Hospital-based intravenous immunoglobulin,SE
2019-01-30069,2019,Hwang 2019 JCO Clin Cancer Inform,200000,no screening VERSUS Universal hepatitis B screening using HBsAg and anti-HBc tests IN Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- low reactivation risk awaiting cancer therapies.,30892921,Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- low reactivation risk awaiting cancer therapies.,no screening,Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.,Universal hepatitis B screening using HBsAg and anti-HBc tests,SW
2019-01-30069,2019,Hwang 2019 JCO Clin Cancer Inform,Cost-Saving,universal hepatitis b screening VERSUS None IN Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- high reactivation risk awaiting anticancer therapies.,30892921,Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- high reactivation risk awaiting anticancer therapies.,universal hepatitis b screening,Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.,None,SE
2019-01-30069,2019,Hwang 2019 JCO Clin Cancer Inform,Cost-Saving,universal hepatitis b screening VERSUS Selective hepatitis B screening based on a risk tool IN Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- high reactivation risk awaiting anti-cancer therapies.,30892921,Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- high reactivation risk awaiting anti-cancer therapies.,universal hepatitis b screening,Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.,Selective hepatitis B screening based on a risk tool,SE
2019-01-30069,2019,Hwang 2019 JCO Clin Cancer Inform,Cost-Saving,universal hepatitis b screening VERSUS Selective hepatitis B screening using risk tool IN Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- lower reactivation risk awaiting cancer therapies.,30892921,Specific disease- cancer; Age- >=65 years; Gender- Both; Country- United States; Other- lower reactivation risk awaiting cancer therapies.,universal hepatitis b screening,Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy.,Selective hepatitis B screening using risk tool,SE
2019-01-29989,2019,Peters 2019 J Vasc Surg,46000,endovascular revascularization treatment VERSUS Conservative treatment IN Specific disease- critical limb ischemia ; Age- >=65 years; Gender- Male; Country- Netherlands.,30922757,Specific disease- critical limb ischemia ; Age- >=65 years; Gender- Male; Country- Netherlands.,endovascular revascularization treatment,Cost-effectiveness of the treatments for critical limb ischemia in the elderly population.,Conservative treatment,NE
2019-01-29786,2019,Dilokthornsakul 2019 Heart Lung Circ,21000,Apixaban 5 mg VERSUS Warfarin (INR 2 - 3) IN Specific disease- Non-Valvular Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,31000364,Specific disease- Non-Valvular Atrial Fibrillation; Age- Adult; Gender- Both; Country- Thailand.,Apixaban 5 mg,Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.,Warfarin (INR 2 - 3),NE
1 2 3 4 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
